Course: Navigating the Expanding Treatment Landscape in NSCLC: Addressing Key Targets to Improve Access and Outcomes in Rural and Underserved Communities
CME Credits: 0.00
Released: 2026-01-15
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of total lung cancer cases and is the leading cause of cancer-related death in the United States. Despite recent advances in treatment, the 5-year relative survival for advanced/metastatic NSCLC remains relatively low. Management is especially challenging in rural and underserved communities, where patients face barriers such as long travel distances and limited access to oncology specialty care despite having a higher incidence of lung cancer and cancer-related mortality than urban areas. In this on-demand CME/CE activity, expert faculty will review the safe and effective use of novel therapies for patients with advanced/metastatic NSCLC—including HER2- and TROP2-directed antibody-drug conjugates, immunotherapy, and combination regimens—as well as the critical role of biomarker testing to guide therapeutic decision-making. Team-based strategies to improve cancer care and management of treatment-related adverse events in rural and underserved settings will also be discussed. This enduring activity is a recorded session from Oncology Congress that took place on October 25, 2025.
Upon completion of this activity, participants should be better able to:
View Full Course